{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:10:15Z","timestamp":1784005815574,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T00:00:00Z","timestamp":1518048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1245\/s10434-018-6337-5","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T16:33:00Z","timestamp":1518107580000},"page":"2159-2164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma"],"prefix":"10.1245","volume":"25","author":[{"suffix":"Jr.","given":"H. Richard","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"key":"6337_CR1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1200\/JCO.1983.1.6.386","volume":"1","author":"K Antman","year":"1983","unstructured":"Antman K, Pomfret F, Aisner J, et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol. 1983;1:386\u20136.","journal-title":"J Clin Oncol."},{"key":"6337_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/sonc.2002.30236","volume":"29","author":"PH Sugarbaker","year":"2002","unstructured":"Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin. Oncol 2002;29:51\u201361.","journal-title":"Semin. Oncol"},{"key":"6337_CR3","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605\u2013621.","DOI":"10.1016\/S1055-3207(03)00045-0"},{"key":"6337_CR4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0016-5085(19)33323-2","volume":"63","author":"C Moertel","year":"1972","unstructured":"Moertel C. Peritoneal mesothelioma. Gastroenterology. 1972;63:346\u201350.","journal-title":"Gastroenterology."},{"key":"6337_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4149\/neo_2014_053","volume":"61","author":"H Kaya","year":"2014","unstructured":"Kaya H, Sezgi C, Tanrikulu AC, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma. 2014;61:433\u201338.","journal-title":"Neoplasma."},{"key":"6337_CR6","first-page":"343","volume":"134","author":"HR Alexander","year":"2007","unstructured":"Alexander HR, Hanna N, Pingpank JF. Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma. Cancer Treat Res. 2007;134:343\u201355.","journal-title":"Cancer Treat Res."},{"key":"6337_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/annonc\/mdp307","volume":"21","author":"P Manzini Vde","year":"2010","unstructured":"Manzini Vde P, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010; 21: 348\u201353.","journal-title":"Ann Oncol."},{"issue":"1","key":"6337_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","volume":"142","author":"AN Husain","year":"2018","unstructured":"Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 Update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018;142(1):89\u2013108.","journal-title":"Arch Pathol Lab Med"},{"key":"6337_CR9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/PAS.0b013e318033e7a8","volume":"31","author":"CE Comin","year":"2007","unstructured":"Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31:1139\u201348.","journal-title":"Am J Surg Pathol."},{"key":"6337_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res."},{"issue":"9","key":"6337_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/cncr.25640","volume":"117","author":"TD Yan","year":"2011","unstructured":"Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer 2011;117(9):1855\u201363.","journal-title":"Cancer"},{"key":"6337_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","volume":"153","author":"HR Alexander Jr","year":"2013","unstructured":"Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779\u201386.","journal-title":"Surgery."},{"issue":"5","key":"6337_CR13","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis. Ann Surg Oncol. 2015;22(5):1686\u201393.","journal-title":"Ann Surg Oncol."},{"key":"6337_CR14","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140\u201348.","journal-title":"Eur J Cancer."},{"key":"6337_CR15","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237\u201342.","journal-title":"J Clin Oncol."},{"key":"6337_CR16","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1245\/s10434-017-5834-2","volume":"24","author":"YC Li","year":"2017","unstructured":"Li YC, Khashab T, Terhune J et al. Preoperative thrombocytosis predicts shortened survival in patients with malignant peritoneal mesothelioma undergoing operative cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2017;24:2259\u201365.","journal-title":"Ann Surg Oncol."},{"key":"6337_CR17","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","volume":"21","author":"JT Miura","year":"2014","unstructured":"Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21:3947\u201353.","journal-title":"Ann Surg Oncol."},{"key":"6337_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/PAT.0000000000000181","volume":"46","author":"S Liu","year":"2014","unstructured":"Liu S, Staats P, Lee M, et al. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology. 2014;46:604\u201309.","journal-title":"Pathology."},{"key":"6337_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/cncr.20836","volume":"103","author":"TD Yan","year":"2005","unstructured":"Yan TD, Haveric N, Carmignani CP, et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103:839\u201349.","journal-title":"Cancer."},{"key":"6337_CR20","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1245\/s10434-012-2236-3","volume":"19","author":"RN Low","year":"2012","unstructured":"Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2012;19:1394\u20131401.","journal-title":"Ann Surg Oncol."},{"key":"6337_CR21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","volume":"21","author":"D Magge","year":"2014","unstructured":"Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21:1159\u201365.","journal-title":"Ann Surg Oncol."},{"key":"6337_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","volume":"7","author":"PA Janne","year":"2005","unstructured":"Janne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40\u201346.","journal-title":"Clin Lung Cancer."},{"key":"6337_CR23","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet."},{"key":"6337_CR24","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, et al. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093\u20131100.","journal-title":"Ann Surg Oncol."},{"key":"6337_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"65","author":"V Kepenekian","year":"2016","unstructured":"Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer. 2016;65:69\u201379.","journal-title":"Eur J Cancer."},{"key":"6337_CR26","doi-asserted-by":"publisher","first-page":"e105919","DOI":"10.1371\/journal.pone.0105919","volume":"9","author":"R Kanteti","year":"2014","unstructured":"Kanteti R, Dhanasingh I, Kawada I, et al. MET and PI3K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS ONE. 2014;9:e105919.","journal-title":"PLoS One."},{"key":"6337_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cncr.25555","volume":"117","author":"S Varghese","year":"2011","unstructured":"Varghese S, Chen Z, Bartlett DL, et al. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2011;117:361\u201371.","journal-title":"Cancer."},{"issue":"9","key":"6337_CR28","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio M, Scherpereel A, Calabro L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261\u201373.","journal-title":"Lancet Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-018-6337-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6337-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6337-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T19:46:31Z","timestamp":1581968791000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-018-6337-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["6337"],"URL":"https:\/\/doi.org\/10.1245\/s10434-018-6337-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,8]]},"assertion":[{"value":"11 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}